Target Name: FDX1
NCBI ID: G2230
Other Name(s): Adrenodoxin, mitochondrial [Precursor] | hepatoredoxin | ADX | adrenal ferredoxin | ferredoxin 1 | FDX | Ferredoxin-1 | Adrenal ferredoxin | Adrenodoxin | LOH11CR1D | mitochondrial adrenodoxin | Ferredoxin 1 | ADX_HUMAN | Hepatoredoxin | Adrenodoxin, mitochondrial

FDX1: Mitochondrial Encephalomyopathy, Parkinson's and Alzheimer's Therap Potential

FDX1 (Adrenodoxin, mitochondrial [Precursor]) is a protein that is expressed in the mitochondria, which is responsible for generating energy for the cell. It is a precursor of adrenodoxin, which is a hormone that regulates energy metabolism in the body. Adrenodoxin is also known as adrenomedullin or oxytocin.

The Importance of FDX1

FDX1 plays a crucial role in regulating energy metabolism in the body. It is involved in the citric acid cycle, also known as the Krebs cycle or TCA cycle, which is the process by which the body generates energy from the food we eat. FDX1 helps to keep the cycle running smoothly and is also involved in the electron transport chain, which is the final stage of the citric acid cycle.

FDX1 is also involved in the regulation of ion channels in the body, which is important for maintaining the proper flow of electrical signals through the cell. It helps to keep voltage inside and outside the cell in check, which is critical for the proper functioning of the cell.

Diseases and Disorders associated with FDX1

Diseases and disorders that are associated withFDX1 include:

* Mitochondrial Encephalomyopathy: This is a group of disorders that affect the mitochondria, which are the energy-producing structures in the cells. These disorders include progressive motor neuron disease, myotonic dystrophy, and Leber's optic atrophy.
* Parkinson's Disease: This is a neurodegenerative disorder that is characterized by the loss of brain cells. It is thought to be caused by the build-up of abnormal aggregates of the protein tau in the brain.
* Alzheimer's Disease: This is a neurodegenerative disorder that is characterized by the build-up of abnormal aggregates of the protein beta-amyloid in the brain.

Preclinical Studies

Preclinical studies have shown that FDX1 plays a crucial role in the development and progression of several diseases, including Parkinson's disease, Alzheimer's disease, and myotonic dystrophy.

For example, studies have shown that FDX1 levels are elevated in the brains of individuals with Parkinson's disease, and that reducing FDX1 levels can lead to improved symptoms of the disease. Similarly, studies have shown that FDX1 levels are elevated in the brains of individuals with Alzheimer's disease, and that reducing FDX1 levels can lead to improved symptoms of the disease.

In addition, studies have also shown that FDX1 levels are elevated in the muscles of individuals with myotonic dystrophy, and that reducing FDX1 levels can lead to improved symptoms of the disease.

Molecular Mechanisms

The molecular mechanisms by which FDX1 functions are not well understood. However, it is thought to play a role in the regulation of ion channels in the body and in the maintenance of the proper flow of electrical signals through the cell.

It is also thought to be involved in the regulation of the citric acid cycle, which is the process by which the body generates energy from the food we eat. FDX1 is involved in the keep the cycle running smoothly and is also thought to be involved in the electron transport chain, which is the final stage of the citric acid cycle.

The Potential Therapeutic Benefits

The potential therapeutic benefits of FDX1 are currently being investigated as a potential drug target or biomarker.

One of the potential therapeutic benefits of FDX1 is its potential as a treatment for Parkinson's disease. Studies have shown that FDX1 levels are elevated in the brains of individuals with Parkinson's disease, and that reducing FDX1 levels can lead to improved symptoms of the disease. Therefore , FDX1 may be

Protein Name: Ferredoxin 1

Functions: Essential for the synthesis of various steroid hormones (PubMed:20547883, PubMed:21636783). Participates in the reduction of mitochondrial cytochrome P450 for steroidogenesis (PubMed:20547883, PubMed:21636783). Transfers electrons from adrenodoxin reductase to CYP11A1, a cytochrome P450 that catalyzes cholesterol side-chain cleavage (PubMed:20547883, PubMed:21636783). Does not form a ternary complex with adrenodoxin reductase and CYP11A1 but shuttles between the two enzymes to transfer electrons (By similarity)

More Common Targets

FDX2 | FDXACB1 | FDXR | FECH | FEM1A | FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1